The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.

The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
复制标题

基于硼替佐米的化疗治疗免疫球蛋白轻链淀粉样变性的疗效和安全性：系统评价和荟萃分析。

DOI：
10.1016/j.ejim.2019.08.011
复制
发表时间：
2019-08
期刊：
European Journal of Internal Medicine
影响因子：
8
通讯作者：
Sun Shiren
Sun Shiren
中科院分区：
医学2区
文献类型：
--
作者：
Liu Baojian;Bai Ming;Wang Yan;Wang Di;Zhao Jin;Li Lu;Dong Ruijuan;Sun Shiren

文献摘要

参考文献

相似文献

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis
DOI： 10.1016/j.clml.2015.07.200
发表时间： 2014-12
期刊： Clinical Lymphoma, Myeloma & Leukemia
影响因子： --
作者：
E. Kastritis;X. Leleu;B. Arnulf;E. Zamagni;M. Cibeira;F. Kwok;P. Mollee;R. Hájek;P. Moreau
通讯作者： E. Kastritis;X. Leleu;B. Arnulf;E. Zamagni;M. Cibeira;F. Kwok;P. Mollee;R. Hájek;P. Moreau
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
DOI： 10.1038/bcj.2017.47
发表时间： 2017-06-16
期刊： Blood cancer journal
影响因子： 12.8
作者：
Kastritis E;Gavriatopoulou M;Roussou M;Fotiou D;Ziogas DC;Migkou M;Eleutherakis-Papaiakovou E;Panagiotidis I;Kanellias N;Psimenou E;Papadopoulou E;Pamboucas C;Manios E;Gakiopoulou H;Ntalianis A;Tasidou A;Giannouli S;Terpos E;Dimopoulos MA
通讯作者： Dimopoulos MA
At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment
DOI： 10.1007/s00277-017-3132-5
发表时间： 2017-09
期刊： Annals of Hematology
影响因子： 3.5
作者：
K. Shen;Jun Feng;Xu-fei Huang;Chun-lan Zhang;Cong-li Zhang;Xin-xin Cao;Lu Zhang;Dao-bin Zhou
通讯作者： K. Shen;Jun Feng;Xu-fei Huang;Chun-lan Zhang;Cong-li Zhang;Xin-xin Cao;Lu Zhang;Dao-bin Zhou
Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study
DOI： 10.1007/s12185-016-2128-6
发表时间： 2017-03-01
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY
影响因子： 2.1
作者：
Katoh, Nagaaki;Ueno, Akihiro;Ikeda, Shu-ichi
通讯作者： Ikeda, Shu-ichi
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
DOI： 10.1038/leu.2014.218
发表时间： 2014-12-01
期刊： LEUKEMIA
影响因子： 11.4
作者：
Venner, C. P.;Gillmore, J. D.;Wechalekar, A. D.
通讯作者： Wechalekar, A. D.